The pressing emergency exclusion provided for in the trade agreements have been invoked. This RFP is BEING PUT IN PLACE BY CANADA AS PART OF ITS RESPONSE TO THE COVID-19 PANDEMIC therefore, this procurement is excluded from all of the obligations of all the trade agreements.
The National Research Council of Canada is building a new Biologic Manufacturing Centre (BMC) that will house the process and equipment for the production and the quality control of vaccines intended for human use.
The vaccines are intended for the Canadian market, regulated by Health Canada under the authority of the Food and Drugs Act. The facility will require being compliant with Canadian Good Manufacturing Practices (GMP).
The new manufacturing rooms and airlocks (personnel and material) will be built in an extension to the existing NRC’s premises located in Montreal, Quebec and will consist of classified grade C and D areas.
The facility will include equipment and infrastructures necessary for viral seed stock preparation, subculture, cell culture and viral production, purification, final fill, secondary packaging, warehousing and quality control laboratory.
